Cancer is the second leading cause of mortality globally which remains a continuing threat
to human health today. Drug insensitivity and resistance are critical hurdles in cancer …

Thyroid cancer is the most common endocrine cancer. The discovery of new biomarkers for
thyroid cancer has significantly improved the understanding of the molecular pathogenesis …

The diagnostic modalities, stratification tools, and treatment options for patients with thyroid
cancer have rapidly evolved since the development of the American Thyroid Association …

The knowledge on thyroid cancer biology has grown over the past decade. Thus, diagnostic
and therapeutic strategies to manage thyroid cancer are rapidly evolving. With new insights …

The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …

Based on experimental data, the inhibition of the MAPkinase pathway in patients with
radioiodine-refractory thyroid cancer was capable of inducing a redifferentiation. Preliminary …

A high incidence of cancer has given rise to the development of more anti-tumor drugs. From
2015 to 2020, fifty-six new small-molecule anticancer drugs, divided into ten categories …

Abstract The SEL-I-METRY trial (EudraCT No 2015-002269-47) is the first multicentre trial to
investigate the role of 123 I and 131 I SPECT/CT-based tumour dosimetry to predict …

With the exception of non-melanoma skin cancer, breast cancer is the most frequently
diagnosed malignant disease among women, with the majority of mortality being attributable …

Radioiodine therapy (RAI) is a standard and effective therapeutic approach for differentiated
thyroid cancers (DTCs) based on the unique capacity for iodide uptake and accumulation of …